Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SinVital Conceive Plus Male is a combination therapeutic regimen used for the treatment of male infertility, specifically targeting oligospermia (low sperm count) and asthenospermia (low sperm motility). It consists of SinVital, a pharmaceutical-grade levocarnitine oral solution, and Conceive Plus Male Fertility Support, a comprehensive nutritional supplement. SinVital was developed and clinically validated in collaboration with the Andrology Center of Peking University First Hospital, serving as a foundational therapy to improve sperm energy metabolism by facilitating the transport of long-chain fatty acids into the mitochondrial matrix for beta-oxidation. The Conceive Plus component provides a synergistic blend of vitamins (A, C, E, B-complex), minerals (Zinc, Selenium), and antioxidants (L-arginine, Maca, Ginseng) that support spermatogenesis and protect sperm cells from oxidative stress. This combination is widely utilized in clinical practice to optimize sperm quality and enhance male reproductive potential.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SinVital Conceive Plus Male.